EXTRACELLULAR MATRIX IS A COST EFFECTIVE OPTION FOR THE MANAGEMENT OF VENOUS LEG ULCERS

Published Nov 20, 2014
Fort Worth, TX, USA - Venous leg ulcers (VLUs) affect up to 2.5 million people per year in the USA at an estimated cost of 14.9 billion dollars annually.  The longer it takes to heal a VLU, the greater the financial burden to the health care system. Cellular/tissue-derived products (CTPs) are often used in conjunction with compression therapy to treat refractory cases of VLU, however, little is known regarding the cost-effectiveness of the most commonly used CTPs. Researchers from Strategic Solutions Inc. conducted a cost-effectiveness analysis of three frequently used CTP VLU therapies using economic and clinical outcome information available in the medical literature.  The study determined that a porcine derived extracellular matrix (ECM) was a cost saving therapeutic option when compared to human skin equivalent (HSE) and living skin equivalent (LSE). The expected wound closure rates were 75% for ECM, 70% for LSE and 69% for HSE. The cost per episode of VLU care was estimated at $6,732 for ECM compared to $10,638 for HSE and $11,237 for LSE. “The higher wound closure rate shown by the ECM product provided substantial clinical benefit for patients with an economic benefit for payers. The longer a wound remains unhealed the greater the additional costs,” said lead researcher, Dr. Marissa J. Carter, PhD. “Closing the wound earlier with an ECM improves patient outcomes, reduces health care resource utilization and lowers the overall costs of VLU care.” The full study, “Cost-Effectiveness of Three Adjunct Cellular/Tissue-Derived Products Used in the Management of Chronic Venous Leg Ulcers,” is published in Value in Health.

Related Stories

Rethinking Medication Adherence: A Stakeholder Blueprint

May 12, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a report from its Medication Adherence and Persistence Special Interest Group that provides valuable insights into the perspectives of key stakeholders on interventions to improve medication adherence. The report, “Stakeholders’ Perspectives on Medication Adherence Enhancing Interventions: An ISPOR Report,” was published in the May 2025 issue of Value in Health.

New Research Reveals Surprising Trends in Women's Health Economics Authorship

May 12, 2025

Value in Health, the official journal of ISPOR announced the publication of new research analyzing women's representation in authorship of papers submitted to and published in Value in Health. The report, “How Well Are Women Represented in Authorship in HEOR? An Analysis of Value in Health: An ISPOR Report,” was published in the May 2025 issue of Value in Health.

Redefining Value in Care for Alzheimer's Disease and Dementia

Apr 8, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced the publication of a special themed section of research papers that provide crucial insights into the complex health economics of Alzheimer's disease and related dementias (ADRD), offering a roadmap for future research and policy as the aging population grows and novel treatments emerge.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×